PEG 4 -Modified FAP-CAIX Heterodimeric Radioligand for Precision Imaging and Radiotherapy
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c00751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Yue Feng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District 400010, Chongqing…. Hauptthemen laut MEDLINE: Polyethylene Glycols, Radiopharmaceuticals, Carbonic Anhydrase IX, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing Municipality, The Central Guidance for Local Science and Technology Development, Mianyang Science and Technology Bureau Projects.
Abstract (Originalsprache)
Tumor heterogeneity severely limits the efficacy of single-targeted radiopharmaceuticals. FAP and CAIX are important biomarkers overexpressed in tumors and the tumor microenvironment. We designed a PEG4-modified heterodimeric radioligand, FC, for dual targeting of FAP and CAIX. FC showed high binding affinity toward FAP (IC50 = 18.2 ± 0.23 nM). [68Ga]Ga-FC exhibited significantly higher tumor uptake than monomeric tracers in FAP- or CAIX-positive tumor models at 120 min postinjection. PEG4 modification markedly enhanced hydrophilicity, tumor retention, and in vivo stability. Mirco-SPECT imaging showed strong tumor accumulation of [177Lu]Lu-FC up to 168 h. A single dose of [177Lu]Lu-FC (29.6 MBq) achieved complete tumor suppression in HEK293-FAP tumor-bearing mice with no obvious organ toxicity. [68Ga]Ga/[177Lu]Lu-FC represents a promising theranostic agent for FAP-positive malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, No.74 Linjiang Rd, Yuzhong District 400010, Chongqing, China.
- Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Jiangyang District 646000, Luzhou, China.
- Institute of Nuclear Physics and Chemistry, China Academy of Engineering Physics, Mianyang 621900, China.
- Targeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province, Mianyang 621000, China.
ORCID-Profile: Liang Cai
Förderung
- Natural Science Foundation of Chongqing Municipality
- The Central Guidance for Local Science and Technology Development, Mianyang Science and Technology Bureau Projects
Zitieren
APA
Feng, Y., Zhang, H., Wang, Z., Liu, Y., Xiang, X., Rao, M., Xie, J., Yang, X., & Cai, L. (2026). PEG 4 -Modified FAP-CAIX Heterodimeric Radioligand for Precision Imaging and Radiotherapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c00751
Vancouver
Feng Y, Zhang H, Wang Z, Liu Y, Xiang X, Rao M, et al. PEG 4 -Modified FAP-CAIX Heterodimeric Radioligand for Precision Imaging and Radiotherapy. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c00751
BibTeX
@article{Feng2026,
author = {Feng, Yue and Zhang, Huihui and Wang, Zi and Liu, Yanggang and Xiang, Xiaojiao and Rao, Maohua and Xie, Jiajian and Yang, Xia and Cai, Liang},
title = {PEG 4 -Modified FAP-CAIX Heterodimeric Radioligand for Precision Imaging and Radiotherapy},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c00751}
}
EUVIMED